Deferasirox in patients with iron overload secondary to hereditary hemochromatosis: Results of a 1-yr Phase 2 study

European Journal of Haematology

Volumn 95, Issue 6, 2015, Pages 545-550

  Cançado, Rodolfo ^a   Melo, Murilo R ^a   de Moraes Bastos, Roberto ^a   Santos, Paulo C J L ^b   Guerra Shinohara, Elivira M ^b   Chiattone, Carlos ^a   Ballas, Samir K ^c  

^a FACULDADE DE CIÊNCIAS MÉDICAS DA SANTA CASA DE SÃO PAULO   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Chelation therapy; Deferasirox; Erythrocytapheresis; Hereditary hemochromatosis; Iron overload; Phlebotomy; Transfusional siderosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATININE; DEFERASIROX; FERRITIN; IRON; TRANSFERRIN; BENZOIC ACID DERIVATIVE; BIOLOGICAL MARKER; HEMOCHROMATOSIS PROTEIN; HFE PROTEIN, HUMAN; HLA ANTIGEN CLASS 1; IRON CHELATING AGENT; MEMBRANE PROTEIN; TRIAZOLE DERIVATIVE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BETA THALASSEMIA; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; FEMALE; FERRITIN BLOOD LEVEL; GENE MUTATION; HEMOCHROMATOSIS; HEREDITARY HEMOCHROMATOSIS; HEREDITARY SPHEROCYTOSIS; HUMAN; IRON OVERLOAD; LIVER LEVEL; MALE; MIDDLE AGED; NAUSEA; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PHLEBOTOMY; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT DURATION; CLINICAL TRIAL; COMPLICATION; GENETICS; MEAN CORPUSCULAR VOLUME; MUTATION; TIME FACTOR; TREATMENT OUTCOME;

ADULT; AGED; BENZOATES; BIOMARKERS; ERYTHROCYTE INDICES; FEMALE; HEMOCHROMATOSIS; HEMOCHROMATOSIS PROTEIN; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MUTATION; TIME FACTORS; TREATMENT OUTCOME; TRIAZOLES;

EID: 84949945320     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12530     Document Type: Article

References (30)

1. European Association for the Study of the Liver. EASL clinical practice guidelines for HFE hemochromatosis. J Hepatol 2010;53:3-22.
2. Pietrangelo A. Hepcidin in human iron disorders: therapeutic implications. J Hepatol 2011;54:173-81.
3. Gan EK, Powell LW, Olynyk JK. Natural history and management of HFE-hemochromatosis. Semin Liver Dis 2011;31:293-301.
4. Niederau C, Fischer R, Purschel A, Stremmel W, Haussinger D, Strohmeyer G. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 1996;110:1107-19.
5. Davis WD Jr, Arrowsmith WR. The treatment of hemochromatosis by massive venesection. Ann Intern Med 1953;39:723-34.
6. Adams PC, Barton JC. How I treat hemochromatosis. Blood 2010;116:317-25.
7. McDonnell SM, Preston BL, Jewell SA, Barton JC, Edwards CQ, Adams PC, Yip R. A survey of 2851 patients with hemochromatosis: symptoms and response to treatment. Am J Med 1999;106:619-24.
8. McDonnell SM, Grindon AJ, Preston BL, Barton JC, Edwards CQ, Adams PC. A survey of phlebotomy among persons with hemochromatosis. Transfusion 1999;39:651-6.
9. Hicken BL, Tucker DC, Barton JC. Patient compliance with phlebotomy therapy for iron overload associated with hemochromatosis. Am J Gastroenterol 2003;98:2072-7.
10. Rombout-Sestrienkova E, Nieman FH, Essers BA, et al. Erythrocytapheresis versus phlebotomy in the initial treatment of HFE hemochromatosis patients: results from a randomized trial. Transfusion 2012;52:470-7.
11. Poullin P, Lefevre PA. Effectiveness of therapeutic erythrocytapheresis to achieve iron depletion in hereditary type 1 hemochromatosis: report of 30 cases. Transfus Clin Biol 2011;18:553-8.
12. Fernandez-Mosteirin N, Salvador-Osuna C, Garcia-Erce JA, Orna E, Perez-Lungmus G, Giralt M. Comparison between phlebotomy and erythrocytapheresis of iron overload in patients with HFE gene mutations. Med Clin (Barc) 2006;127:409-12.
13. Mariani R, Pelucchi S, Perseghin P, Corengia C, Piperno A. Erythrocytapheresis plus erythropoietin: an alternative therapy for selected patients with hemochromatosis and severe organ damage. Haematologica 2005;90:717-8.
14. Cappellini MD, Bejaoui M, Agaoglu L, et al. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia. Clin Ther 2007;29:909-17.
15. Armstrong EP, Skrepnek GH, Sasane M, Snodgrass SM, Ballas SK. Long-term persistency and costs associated with the use of iron chelation therapies in the treatment of Sickle cell disease within Medicaid programs. J Med Econ 2013;16:10-8.
16. Taher A, Al Jefri A, Elalfy MS, Al Zir K, Daar S, Rofail D, Baladi JF, Habr D, Kriemler-Krahn U, El-Beshlawy A. Improved treatment satisfaction and convenience with deferasirox in iron-overloaded patients with beta-Thalassemia: results from the ESCALATOR Trial. Acta Haematol 2010;123:220-5.
17. Jordan LB, Vekeman F, Sengupta A, Corral M, Guo A, Duh MS. Persistence and compliance of deferoxamine versus deferasirox in Medicaid patients with sickle-cell disease. J Clin Pharm Ther 2012;37:173-81.
18. Ballas SK. Iron overload is a determinant of morbidity and mortality in adult patients with sickle cell disease. Semin Hematol 2001;38(1 Suppl 1):30-6.
19. Santos PC, Cancado RD, Pereira AC, Chiattone CS, Krieger JE, Guerra-Shinohara EM. HJV hemochromatosis, iron overload, and hypogonadism in a Brazilian man: treatment with phlebotomy and deferasirox. Acta Haematol 2010;124:204-5.
20. Nagler M, Gregor M, Wuillemin WA. Iron chelation with deferasirox in two patients with HFE hemochromatosis and chronic anemia. Acta Haematol 2011;126:119-21.
21. Maeda T, Nakamaki T, Saito B, et al. Hemojuvelin hemochromatosis receiving iron chelation therapy with deferasirox: improvement of liver disease activity, cardiac and hematological function. Eur J Haematol 2011;87:467-9.
22. Phatak P, Brissot P, Wurster M, et al. A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis. Hepatology 2010;52:1671-779.
23. Kontoghiorghes GJ. A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds? Expert Opin Drug Saf 2013;12:605-9.
24. Aslam N, Mettu P, Marsano-Obando LS, Martin A. Deferasirox induced liver injury in haemochromatosis. J Coll Physicians Surg Pak 2010;20:551-3.
25. Ila HB, Topaktas M, Arslan M, Buyukleyla M. Signs of deferasirox genotoxicity. Cytotechnology 2014;66:647-54.
26. Ballas SK, McCarthy WF, Guo N, DeCastro L, Bellevue R, Barton BA, Waclawiw MA. Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. J Natl Med Assoc 2009;101:1046-51.
27. Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA 2014;312:1033-48.
28. Vichinsky E, Onyekwere O, Porter J, et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol 2007;136:501-8.
29. Vichinsky E, Bernaudin F, Forni GL, et al. Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease. Br J Haematol 2011;154:387-97.
30. Kwiatkowski JL, Kim HY, Thompson AA, et al. Chelation use and iron burden in North American and British thalassemia patients: a report from the Thalassemia Longitudinal Cohort. Blood 2012;119:2746-53.